| Firm | Analyst | | Cantor Fitzgerald | Mara Goldstein | | Cowen and Company | Eric Schmidt | | Credit Suisse | Jason Kantor | | Edison Investment Research Limited | Robin Davison | | Leerink Swann | Marko Kozul | | McNicoll, Lewis & Vlak LLC | George B. Zavoico | | RBC Capital Markets Wealth Management | Adnan Butt | | Roth Capital Partners, L.L.C | Joseph Pantginis | | Wedbush Securities, Inc. | David M. Nierengarten | | Wells Fargo | Matthew J. Andrews |
|
Analyst Ratings
|
| 1-Strong Buy | 4 | | 2-Buy | 5 | | 3-Hold | 0 | | 4-Underperform | 0 | | 5-Sell | 0 |
|
|  | Mean Recommendation: 1.6
| | Sell |  | Strong Buy |
|
|
|
| Sunesis Pharmaceuticals, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Sunesis Pharmaceuticals, Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Sunesis Pharmaceuticals, Inc. or its management. Sunesis Pharmaceuticals, Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. |
Sunesis is a biopharmaceutical company focused on new oncology therapeutics for the treatment of solid and hematologic cancers.
Listen to recent webcasts of presentation conference calls, earnings calls, and more.
Copyright © Sunesis Pharmaceuticals, Inc. 2010. All Rights Reserved.
